William Blair Investment Management LLC Sells 25,255 Shares of Eli Lilly and Company $LLY

William Blair Investment Management LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 55.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,567 shares of the company’s stock after selling 25,255 shares during the period. William Blair Investment Management LLC’s holdings in Eli Lilly and Company were worth $16,033,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Quotient Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 11.2% during the 2nd quarter. Quotient Wealth Partners LLC now owns 3,726 shares of the company’s stock worth $2,905,000 after buying an additional 374 shares in the last quarter. MPS Loria Financial Planners LLC boosted its holdings in shares of Eli Lilly and Company by 1.9% during the 2nd quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock worth $545,000 after buying an additional 13 shares in the last quarter. Manchester Financial Inc. boosted its holdings in shares of Eli Lilly and Company by 58.0% during the 2nd quarter. Manchester Financial Inc. now owns 1,503 shares of the company’s stock worth $1,172,000 after buying an additional 552 shares in the last quarter. Private Wealth Management Group LLC boosted its holdings in shares of Eli Lilly and Company by 18.0% during the 2nd quarter. Private Wealth Management Group LLC now owns 190 shares of the company’s stock worth $148,000 after buying an additional 29 shares in the last quarter. Finally, Koshinski Asset Management Inc. boosted its holdings in shares of Eli Lilly and Company by 9.1% during the 2nd quarter. Koshinski Asset Management Inc. now owns 4,673 shares of the company’s stock worth $3,643,000 after buying an additional 391 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Jamere Jackson purchased 200 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 in the last three months. 0.14% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LLY shares. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. The Goldman Sachs Group upped their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $939.12.

Eli Lilly and Company Trading Down 1.9%

NYSE LLY opened at $803.53 on Monday. The firm has a market capitalization of $760.51 billion, a P/E ratio of 52.52, a PEG ratio of 1.15 and a beta of 0.47. The business has a fifty day simple moving average of $753.09 and a 200 day simple moving average of $765.70. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.